ATE353339T1 - METHOD AND COMPOSITION FOR INHIBITING NEOPLASTIC CELL GROWTH - Google Patents
METHOD AND COMPOSITION FOR INHIBITING NEOPLASTIC CELL GROWTHInfo
- Publication number
- ATE353339T1 ATE353339T1 AT04007617T AT04007617T ATE353339T1 AT E353339 T1 ATE353339 T1 AT E353339T1 AT 04007617 T AT04007617 T AT 04007617T AT 04007617 T AT04007617 T AT 04007617T AT E353339 T1 ATE353339 T1 AT E353339T1
- Authority
- AT
- Austria
- Prior art keywords
- present
- polypeptides
- methods
- cell growth
- neoplastic cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention concerns methods and compositions for inhibiting neoplastic cell growth. In particular, the present invention concerns antitumor compositions and methods for the treatment of tumors. The invention further concerns screening methods for identifying growth inhibitory, e.g., antitumor compounds. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11329698P | 1998-12-22 | 1998-12-22 | |
PCT/US1999/005028 WO1999046281A2 (en) | 1998-03-10 | 1999-03-08 | Novel polypeptides and nucleic acids encoding the same |
US13023299P | 1999-04-21 | 1999-04-21 | |
US13144599P | 1999-04-28 | 1999-04-28 | |
US13428799P | 1999-05-14 | 1999-05-14 | |
US14475899P | 1999-07-20 | 1999-07-20 | |
US14569899P | 1999-07-26 | 1999-07-26 | |
PCT/US1999/021090 WO2000015796A2 (en) | 1998-09-16 | 1999-09-15 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
PCT/US1999/021547 WO2000015797A2 (en) | 1998-09-17 | 1999-09-15 | Compositions and methods for the treatment of immune related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE353339T1 true ATE353339T1 (en) | 2007-02-15 |
Family
ID=27557838
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07001711T ATE432987T1 (en) | 1998-12-22 | 1999-12-02 | METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTH |
AT04007617T ATE353339T1 (en) | 1998-12-22 | 1999-12-02 | METHOD AND COMPOSITION FOR INHIBITING NEOPLASTIC CELL GROWTH |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07001711T ATE432987T1 (en) | 1998-12-22 | 1999-12-02 | METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTH |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1141284A2 (en) |
JP (5) | JP3993746B2 (en) |
KR (1) | KR100499600B1 (en) |
AT (2) | ATE432987T1 (en) |
AU (1) | AU768230B2 (en) |
CA (1) | CA2353799A1 (en) |
DE (2) | DE69940964D1 (en) |
DK (1) | DK1484338T3 (en) |
ES (2) | ES2281704T3 (en) |
IL (3) | IL143031A0 (en) |
MX (1) | MXPA01006330A (en) |
PT (1) | PT1484338E (en) |
WO (1) | WO2000037638A2 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6808890B2 (en) | 1999-07-28 | 2004-10-26 | Nuvelo, Inc. | Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein |
US6392019B1 (en) | 1997-11-22 | 2002-05-21 | John Ford | Antibodies specific for EGF motif proteins |
US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
EP1032666A1 (en) | 1997-11-22 | 2000-09-06 | Hyseq, Inc. | A NOVEL EGF MOTIF PROTEIN OBTAINED FROM A cDNA LIBRARY OF FETAL LIVER-SPLEEN |
NZ528700A (en) * | 1998-04-08 | 2005-02-25 | Genentech Inc | Novel PRO866 polypeptides and nucleic acids with homology to mindin and spondin proteins |
JP2002518010A (en) | 1998-06-16 | 2002-06-25 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 94 human secreted proteins |
US6960433B1 (en) | 1998-10-19 | 2005-11-01 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
BR0007556A (en) | 1999-01-15 | 2001-10-23 | Biogen Inc | Tweak and tweak receptor antagonists and their use to treat immune disorders |
KR100553300B1 (en) * | 1999-03-08 | 2006-02-20 | 제넨테크, 인크. | Promotion or Inhibition of Angiogenesis and Cardiovascularization |
DE60035693T2 (en) * | 1999-07-20 | 2008-05-15 | Genentech, Inc., South San Francisco | COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNOMATED DISEASES |
HUP0203408A3 (en) * | 1999-12-09 | 2005-01-28 | Sankyo Co | Method of testing remedy or preventive for hyperlipemia |
ATE466882T1 (en) * | 2000-01-12 | 2010-05-15 | Univ Yale | NOGO RECEPTOR-MEDIATED BLOCKADE OF AXONAL GROWTH |
US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
EP1363657A2 (en) | 2000-05-08 | 2003-11-26 | Biogen, Inc. | Method for promoting neovascularization using a tweak agonist and an angiogenic factor |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
WO2002029059A2 (en) | 2000-10-06 | 2002-04-11 | Yale University | Nogo receptor homologs |
US20020111302A1 (en) * | 2000-11-30 | 2002-08-15 | Y. Tom Tang | Novel nucleic acids and polypeptides |
WO2003086311A2 (en) | 2002-04-09 | 2003-10-23 | Biogen, Inc. | Methods for treating tweak-related conditions |
CA2391438A1 (en) * | 2002-05-01 | 2003-11-01 | Procyon Biopharma Inc. | Psp94 diagnostic reagents and assays |
DK2529619T3 (en) | 2005-02-17 | 2016-01-11 | Biogen Ma Inc | Treatment of neurological disorders |
EP1885388B1 (en) | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Treating and evaluating inflammatory disorders |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
WO2007008732A2 (en) | 2005-07-07 | 2007-01-18 | Yale University | Compositions and methods for suppressing axonal growth inhibition |
KR20150055628A (en) | 2005-11-04 | 2015-05-21 | 제넨테크, 인크. | Use of complement pathway inhibitors to treat ocular diseases |
US9044461B2 (en) | 2006-04-07 | 2015-06-02 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
JP5524610B2 (en) * | 2006-04-07 | 2014-06-18 | ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク | Transcobalamin receptor polypeptides, nucleic acids and modulators thereof, and related methods used to regulate cell growth and to treat cancer and cobalamin deficiency |
US7776573B2 (en) | 2006-06-01 | 2010-08-17 | Genentech, Inc. | Crystal structure of CRIg and C3b:CRIg complex |
PL2097455T3 (en) | 2006-11-02 | 2015-04-30 | Genentech Inc | Humanized anti-factor d antibodies |
AR066660A1 (en) | 2007-05-23 | 2009-09-02 | Genentech Inc | PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT |
CR20170001A (en) | 2008-04-28 | 2017-08-10 | Genentech Inc | ANTI FACTOR D HUMANIZED ANTIBODIES |
SG190596A1 (en) | 2008-05-06 | 2013-06-28 | Genentech Inc | Affinity matured crig variants |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
MX2016001854A (en) | 2013-08-12 | 2016-09-06 | Genentech Inc | Compositions and method for treating complement-associated conditions. |
TW201623337A (en) | 2014-05-01 | 2016-07-01 | 建南德克公司 | Anti-Factor D antibody variants and uses thereof |
JP2018536650A (en) | 2015-10-30 | 2018-12-13 | ジェネンテック, インコーポレイテッド | Anti-factor D antibody variant conjugates and uses thereof |
US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
CN114835774B (en) * | 2022-06-29 | 2022-09-27 | 中国农业大学 | Oligopeptide MSL separated from pepper seeds and application thereof in preventing or treating cancers |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ226799A (en) * | 1987-11-06 | 1991-08-27 | Oncogen | Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor |
US5814307A (en) * | 1989-04-10 | 1998-09-29 | Bristol-Myers Squibb Company | Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6 |
US5416192A (en) * | 1990-04-03 | 1995-05-16 | Bristol-Myers Squibb Company | Epithelins: novel cysteine-rich growth modulating proteins |
US5028099A (en) * | 1990-08-08 | 1991-07-02 | Bertucco Leonard J | Trash recycling container |
US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
WO1999055869A1 (en) * | 1998-04-27 | 1999-11-04 | Zymogenetics, Inc. | Novel polypeptide growth factors and materials and methods for making them |
SV1999000069A (en) * | 1998-06-02 | 2000-04-11 | Lilly Co Eli | ANGIOPOYETIN RELATED TO SEQUENCE OF GEN 3 IN FACE SCAR REF. X-12261 |
JP7039446B2 (en) * | 2018-11-29 | 2022-03-22 | 株式会社東芝 | Electronic device |
-
1999
- 1999-12-02 MX MXPA01006330A patent/MXPA01006330A/en not_active Application Discontinuation
- 1999-12-02 DE DE69940964T patent/DE69940964D1/en not_active Expired - Lifetime
- 1999-12-02 DE DE69935085T patent/DE69935085T2/en not_active Expired - Lifetime
- 1999-12-02 AT AT07001711T patent/ATE432987T1/en not_active IP Right Cessation
- 1999-12-02 IL IL14303199A patent/IL143031A0/en not_active IP Right Cessation
- 1999-12-02 PT PT04007617T patent/PT1484338E/en unknown
- 1999-12-02 EP EP99960644A patent/EP1141284A2/en not_active Withdrawn
- 1999-12-02 ES ES04007617T patent/ES2281704T3/en not_active Expired - Lifetime
- 1999-12-02 KR KR10-2001-7007850A patent/KR100499600B1/en not_active IP Right Cessation
- 1999-12-02 AT AT04007617T patent/ATE353339T1/en active
- 1999-12-02 JP JP2000589692A patent/JP3993746B2/en not_active Expired - Fee Related
- 1999-12-02 CA CA002353799A patent/CA2353799A1/en not_active Abandoned
- 1999-12-02 WO PCT/US1999/028565 patent/WO2000037638A2/en active Search and Examination
- 1999-12-02 AU AU17499/00A patent/AU768230B2/en not_active Expired
- 1999-12-02 DK DK04007617T patent/DK1484338T3/en active
- 1999-12-02 ES ES07001711T patent/ES2327785T3/en not_active Expired - Lifetime
-
2005
- 2005-03-10 JP JP2005066569A patent/JP4037876B2/en not_active Expired - Lifetime
- 2005-03-10 JP JP2005066570A patent/JP2005237383A/en not_active Withdrawn
-
2007
- 2007-05-24 JP JP2007138468A patent/JP2007222180A/en active Pending
- 2007-05-24 JP JP2007138469A patent/JP2007291116A/en active Pending
- 2007-09-20 IL IL186153A patent/IL186153A0/en unknown
- 2007-09-20 IL IL186154A patent/IL186154A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL186153A0 (en) | 2008-01-20 |
DK1484338T3 (en) | 2007-06-11 |
WO2000037638A3 (en) | 2000-11-09 |
JP3993746B2 (en) | 2007-10-17 |
WO2000037638A2 (en) | 2000-06-29 |
DE69935085D1 (en) | 2007-03-22 |
MXPA01006330A (en) | 2002-07-02 |
IL186154A0 (en) | 2008-01-20 |
DE69940964D1 (en) | 2009-07-16 |
CA2353799A1 (en) | 2000-06-29 |
JP4037876B2 (en) | 2008-01-23 |
JP2007222180A (en) | 2007-09-06 |
PT1484338E (en) | 2007-05-31 |
AU1749900A (en) | 2000-07-12 |
KR20010084882A (en) | 2001-09-06 |
JP2007291116A (en) | 2007-11-08 |
ES2281704T3 (en) | 2007-10-01 |
KR100499600B1 (en) | 2005-07-07 |
DE69935085T2 (en) | 2007-08-23 |
JP2005245451A (en) | 2005-09-15 |
EP1141284A2 (en) | 2001-10-10 |
ATE432987T1 (en) | 2009-06-15 |
JP2003529317A (en) | 2003-10-07 |
IL143031A0 (en) | 2002-04-21 |
AU768230B2 (en) | 2003-12-04 |
JP2005237383A (en) | 2005-09-08 |
ES2327785T3 (en) | 2009-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE353339T1 (en) | METHOD AND COMPOSITION FOR INHIBITING NEOPLASTIC CELL GROWTH | |
ATE357518T1 (en) | METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTH | |
ATE408419T1 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF A TUMOR | |
ATE380195T1 (en) | COMPOSITIONS AND METHODS FOR TREATING TUMORS | |
IL193149A (en) | Anti il-17c antibody and therapeutic compositions comprising same | |
HK1114636A1 (en) | 1l-17 homologous polypeptides and therapeutic uses thereof | |
WO2002026822A3 (en) | Pumpcn compositions and uses thereof | |
DE60043125D1 (en) | Compositions and methods for tumor treatment | |
KR100468977B1 (en) | Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same | |
ATE439431T1 (en) | COMPOSITION AND METHOD FOR DIAGNOSIS OF TUMORS | |
WO2000032778A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
WO2001049715A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
EP2075335A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
EP1873244A8 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
KR100515858B1 (en) | PRO617 Polypeptides | |
WO2000007545A3 (en) | Apoptosis proteins | |
KR100515857B1 (en) | PRO792 Polypeptides | |
KR100515856B1 (en) | PRO618 Polypeptides | |
KR100515855B1 (en) | PRO351 Polypeptides | |
DK1249491T3 (en) | Nucleic acid that is propagated in human tumors as well as related materials and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1484338 Country of ref document: EP |